BriaCell Awarded New Zealand Patent for its Whole Cell Technology
BriaCell Therapeutics (NASDAQ: BCTX) has secured New Zealand Patent No. 785587 for its whole-cell cancer immunotherapy technology. The patent, valid through February 27, 2037, covers methods for selecting cancer immunotherapy based on HLA allele profile matching.
This development strengthens BriaCell's precision medicine approach, focusing on personalizing immunotherapy for enhanced patient outcomes. The patent is part of the company's broader strategy to build a robust international patent portfolio for global development and commercialization across multiple cancer indications.
BriaCell Therapeutics (NASDAQ: BCTX) ha ottenuto il brevetto neozelandese n. 785587 per la sua tecnologia di immunoterapia oncologica a cellule intere. Il brevetto, valido fino al 27 febbraio 2037, riguarda i metodi per la selezione dell'immunoterapia oncologica basata sull'abbinamento del profilo degli alleli HLA.
Questo risultato rafforza l'approccio di medicina di precisione di BriaCell, focalizzato sulla personalizzazione dell'immunoterapia per migliorare i risultati clinici dei pazienti. Il brevetto fa parte della strategia più ampia dell'azienda di costruire un solido portafoglio internazionale di brevetti per lo sviluppo globale e la commercializzazione in diverse indicazioni oncologiche.
BriaCell Therapeutics (NASDAQ: BCTX) ha obtenido la patente de Nueva Zelanda No. 785587 para su tecnología de inmunoterapia contra el cáncer con células completas. La patente, válida hasta el 27 de febrero de 2037, cubre métodos para seleccionar inmunoterapia contra el cáncer basada en la coincidencia del perfil de alelos HLA.
Este avance fortalece el enfoque de medicina de precisión de BriaCell, centrado en personalizar la inmunoterapia para mejorar los resultados en los pacientes. La patente forma parte de la estrategia más amplia de la compañía para construir un robusto portafolio internacional de patentes para el desarrollo y comercialización global en múltiples indicaciones de cáncer.
BriaCell Therapeutics (NASDAQ: BCTX)는 전체 세포 암 면역치료 기술에 대해 뉴질랜드 특허번호 785587을 획득했습니다. 이 특허는 2037년 2월 27일까지 유효하며, HLA 대립유전자 프로필 매칭을 기반으로 한 암 면역치료 선택 방법을 포함합니다.
이번 성과는 BriaCell의 정밀 의학 접근법을 강화하며, 환자 맞춤형 면역치료를 통해 치료 효과를 향상시키는 데 중점을 둡니다. 이 특허는 다수 암 적응증에 대한 글로벌 개발 및 상용화를 위한 국제 특허 포트폴리오 구축 전략의 일환입니다.
BriaCell Therapeutics (NASDAQ : BCTX) a obtenu le brevet néo-zélandais n° 785587 pour sa technologie d'immunothérapie anticancéreuse à cellules entières. Le brevet, valable jusqu'au 27 février 2037, couvre les méthodes de sélection de l'immunothérapie anticancéreuse basées sur la correspondance du profil des allèles HLA.
Cette avancée renforce l'approche de médecine de précision de BriaCell, qui vise à personnaliser l'immunothérapie pour améliorer les résultats chez les patients. Ce brevet s'inscrit dans la stratégie plus large de l'entreprise visant à constituer un portefeuille international solide de brevets pour le développement et la commercialisation mondiaux dans plusieurs indications cancéreuses.
BriaCell Therapeutics (NASDAQ: BCTX) hat das neuseeländische Patent Nr. 785587 für seine Ganzzell-Krebsimmuntherapie-Technologie gesichert. Das Patent, gültig bis zum 27. Februar 2037, umfasst Methoden zur Auswahl der Krebsimmuntherapie basierend auf der Übereinstimmung des HLA-Allelprofils.
Diese Entwicklung stärkt BriaCells Ansatz der Präzisionsmedizin, der sich auf die Personalisierung der Immuntherapie zur Verbesserung der Patientenergebnisse konzentriert. Das Patent ist Teil der umfassenderen Strategie des Unternehmens, ein robustes internationales Patentportfolio für die globale Entwicklung und Vermarktung bei verschiedenen Krebsindikationen aufzubauen.
- Patent protection in New Zealand secured until 2037
- Patent strengthens intellectual property portfolio for whole-cell immunotherapy technology
- Supports precision medicine approach through HLA allele profile matching
- None.
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces that it has been granted New Zealand Patent No. 785587 titled “WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF”. The patent covers methods of selecting its whole-cell cancer immunotherapy technology for subjects with cancer based on HLA allele profile matching, providing exclusivity through February 27, 2037, and supporting BriaCell’s precision medicine approach aimed at personalizing immunotherapy for improved patient outcomes.
“We are thrilled that the New Zealand Patent Office recognized the innovative nature of BriaCell’s novel whole cell immunotherapy and its potential therapeutic applications for cancer patients,” said Dr. William V. Williams, President and CEO of BriaCell.
The newly granted patent is part of BriaCell’s broader strategy to establish a strong international patent portfolio enabling the global development and commercialization of its immunotherapy platform across multiple cancer indications.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including statements about BriaCell’s novel whole cell immunotherapy having potential therapeutic applications for cancer patients, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ
What patent did BriaCell (BCTX) receive in New Zealand?
How long is BriaCell's new Zealand patent valid?
What technology does BriaCell's new patent cover?
How does this patent fit into BriaCell's overall strategy?
What is the significance of BriaCell's HLA allele profile matching technology?
